Home
/
Blood Sugar & Metabolic

Basic Metabolic Panel Chart Guide

REVIEWED BY
William Maish, MD MBA MPH
Clinical Product Lead
Published
April 18, 2026
Last updated
June 3, 2026
Key takeaway:

A basic metabolic panel measures 8 biomarkers — glucose, sodium, potassium, chloride, carbon dioxide, BUN, creatinine, and sometimes calcium — to assess blood sugar, kidney function, and electrolyte balance. Fasting for 8–12 hours before testing is required for accurate glucose results, and trends across repeat panels reveal more than any single reading.

Read more →
Table of contents

What a basic metabolic panel chart actually measures

Think of your basic metabolic panel chart as a metabolic dashboard. Eight key measurements reveal how three critical systems perform: your blood sugar regulation, kidney filtration, and electrolyte balance.

Glucose shows how well your body processes sugar. Sodium, potassium, chloride, and carbon dioxide reveal electrolyte balance, which affects everything from muscle contractions to nerve signals. Blood urea nitrogen (BUN) and creatinine indicate kidney filtering efficiency. Some panels add calcium, which supports bone health and muscle function.

These biomarkers rarely change independently. When glucose rises consistently, it can stress kidney function over time. When kidneys struggle, electrolyte balance shifts. Potassium in particular influences how pancreatic beta cells secrete insulin, which affects glucose metabolism.

Your basic metabolic panel chart essentially captures a moment in time across these interconnected systems. One out of range result might indicate a temporary fluctuation. Multiple results trending in concerning directions may suggest your body's metabolic foundation needs attention - discuss with your care team.

Normal versus optimal basic metabolic panel chart levels

Laboratory reference ranges show what's statistically normal in the tested population. Specific "optimal" ranges are not formally established in clinical guidelines, but the middle of a given lab's reference range is often used as a functional target.

For glucose, normal fasting ranges span 70-99 mg/dL. Consistently higher glucose, even within normal range, is associated with increased long-term diabetes risk. For creatinine, normal ranges vary by gender and muscle mass, but stable levels over time matter more than hitting specific numbers.

Electrolyte interpretation focuses on balance rather than isolated values. Rather than naming specific narrow "optimal" cutoffs, most clinicians look at whether sodium, potassium, chloride, and carbon dioxide sit near the middle of the laboratory reference range and remain stable over time. Values drifting toward the edges of the range — even while still "normal" — can be worth a conversation with your care team.

Your individual patterns depend on factors like age, activity level, and health history. A 25-year-old athlete might show different electrolyte patterns than a 55-year-old with hypertension. Tracking your personal trends reveals more than comparing against population averages.

What high basic metabolic panel chart levels can mean

Elevated levels across your basic metabolic panel chart often reflect metabolic stress, kidney strain, or dehydration affecting multiple systems simultaneously.

High glucose typically is associated with insulin resistance, prediabetes, or diabetes. But context matters. Stress, illness, certain medications, or eating before a fasting test can temporarily spike glucose. Consistently elevated glucose is linked to blood vessel damage and kidney filtering strain over time.

Elevated BUN and creatinine suggest kidney function decline, but dehydration can temporarily raise both markers. High sodium might indicate dehydration or excessive salt intake. High potassium can result from kidney problems, certain medications, or muscle breakdown. High chloride often mirrors sodium patterns.

Rising carbon dioxide levels might suggest breathing problems or kidney compensation for acid imbalances. High calcium, when included, could indicate overactive parathyroid glands, certain cancers, or excessive vitamin D supplementation.

Multiple elevated markers create more concern than isolated high results. Rising glucose alongside declining kidney markers like eGFR or increasing microalbumin may suggest diabetic kidney damage progressing over time — creatinine itself often rises late in this process, after significant filtration loss has already occurred.

What low basic metabolic panel chart levels can mean

Low levels on your basic metabolic panel chart often point toward nutritional deficiencies, medication effects, or hormonal imbalances disrupting normal metabolic function.

Low glucose can indicate hypoglycemia from medications, excessive alcohol consumption, liver problems, or hormonal disorders affecting insulin regulation. Reactive hypoglycemia is associated with glucose drops after eating certain foods, while fasting hypoglycemia suggests more serious metabolic dysfunction.

Low sodium might result from drinking excessive water, kidney problems, heart failure, or medications like diuretics. Low potassium often indicates inadequate dietary intake, excessive losses from diarrhea or diuretics, or certain hormonal disorders. Low chloride typically mirrors low sodium patterns.

Low carbon dioxide levels might suggest metabolic acidosis from diabetes, kidney disease, or excessive acid production. Low BUN can indicate liver problems, malnutrition, or overhydration diluting concentrations.

Low calcium, when measured, might suggest vitamin D deficiency, parathyroid problems, or inadequate dietary intake. Multiple low electrolytes often indicate medication effects or chronic illness affecting nutrient absorption and retention.

How a basic metabolic panel chart is tested

Getting your basic metabolic panel chart requires a simple blood draw, typically from a vein in your arm. The entire process takes about five minutes once you're called back.

Fasting for 8-12 hours before testing ensures accurate glucose measurements. Water is usually allowed, but check with your provider about medications. Timing matters because glucose fluctuates throughout the day based on meals, stress, and activity.

Results typically return within 24-48 hours for routine testing. Some urgent situations require stat processing within hours. Your blood sample gets analyzed using automated chemistry analyzers that measure multiple components simultaneously from a single tube.

Retest frequency depends on your health status and risk factors. People with diabetes or kidney disease might need quarterly testing. Healthy individuals often test annually or during routine check-ups. Significant changes in symptoms, medications, or health status warrant repeat testing sooner.

Quality control matters. Proper tube filling, timely processing, and avoiding hemolysis (red blood cell breakdown) ensure accurate results. Dehydration or recent illness can temporarily alter results.

What can change your basic metabolic panel chart

Multiple factors can shift your basic metabolic panel chart results, from dietary choices and medications to stress levels and hydration status affecting measurement accuracy.

Diet significantly impacts results. High-sodium foods can temporarily raise fluid volume and blood pressure, though renal regulation typically keeps serum sodium within a narrow range. Inadequate potassium intake from fruits and vegetables can lower potassium over time. Refined carbohydrates and added sugars can elevate glucose, especially in insulin-resistant individuals.

Medications commonly alter results. Diuretics lower sodium and potassium. ACE inhibitors can raise potassium. Metformin helps lower glucose. Steroids can raise glucose and sodium. Always inform your provider about all medications and supplements.

Dehydration concentrates all measured substances, potentially raising sodium, chloride, BUN, and creatinine. Overhydration dilutes concentrations, potentially lowering these same markers. Exercise affects results differently depending on intensity and duration.

Chronic conditions like diabetes, kidney disease, and heart failure progressively alter multiple markers over time. Acute illnesses, infections, and stress can temporarily shift results through hormonal and inflammatory responses.

Connecting basic metabolic panel chart to related biomarkers

Your basic metabolic panel chart provides more insight when viewed alongside related biomarkers that complete the metabolic picture and reveal patterns single tests might miss.

A1C shows your average glucose control over 2-3 months, complementing the single-moment glucose reading. Estimated GFR (eGFR) calculated from creatinine reveals kidney function more precisely than creatinine alone. Albumin and total protein help interpret BUN and creatinine changes.

Magnesium and phosphorus work closely with calcium and potassium for proper cellular function. Liver enzymes help interpret unusual glucose or protein patterns. Thyroid hormones can affect glucose metabolism and electrolyte balance.

Advanced panels might include insulin levels to assess insulin resistance alongside glucose, or microalbumin to help detect early kidney damage before creatinine rises. C-peptide helps distinguish between different types of diabetes when glucose patterns seem unclear.

Pattern recognition across multiple biomarkers reveals more than isolated results. Rising glucose plus normal A1C might suggest stress or recent illness. Stable glucose with rising A1C could indicate worsening diabetes control over time.

Why testing your basic metabolic panel chart is worth it

Regular basic metabolic panel chart testing may help identify metabolic problems before symptoms appear and tracks how well your current health strategies actually work at the cellular level.

Early detection matters enormously. Prediabetes often shows no symptoms but appears clearly in glucose patterns. Early kidney disease rarely produces noticeable symptoms until significant damage occurs. Electrolyte imbalances can be associated with fatigue and muscle issues long before becoming dangerous.

Trending data reveals whether your lifestyle changes translate into measurable improvements. Exercise and dietary modifications should positively impact glucose control over months. Weight loss should improve insulin sensitivity reflected in glucose patterns. Medication adjustments should produce measurable changes in targeted biomarkers.

Your basic metabolic panel chart also reveals how well you tolerate stress, recover from illness, and maintain metabolic stability as you age. Consistent results over time indicate robust metabolic health. Gradual changes might signal the need for proactive interventions.

Understanding these eight key biomarkers empowers you to make informed decisions about diet, exercise, medications, and when to seek medical attention for concerning changes in your metabolic health patterns.

Get comprehensive metabolic testing with Superpower

Understanding your basic metabolic panel chart becomes more powerful when you can track changes over time and see how your results connect to broader health patterns. Raw numbers on a lab report only tell part of your metabolic story.

Superpower's comprehensive blood panels include all basic metabolic panel biomarkers plus dozens of additional markers that reveal the complete picture of your metabolic health. Our platform transforms complex lab results into clear insights you can actually use to optimize your health.

Track your glucose trends alongside A1C and insulin levels. Monitor kidney function through multiple markers beyond just creatinine. See how your electrolyte balance connects to energy levels, exercise performance, and overall wellbeing through personalized analysis.

Explore Superpower's metabolic testing options and start building the complete picture of your metabolic health today.

FAQs

Normal levels vary by biomarker: glucose 70-99 mg/dL, sodium 136-144 mEq/L, potassium 3.5-5.0 mEq/L, chloride 96-106 mEq/L, CO2 20-29 mEq/L, BUN 7-20 mg/dL, and creatinine 0.74-1.35 mg/dL for men, 0.59-1.04 mg/dL for women. The middle of a given lab's reference range is often used as a functional target, though specific optimal cutoffs are not formally established in clinical guidelines.

A basic metabolic panel includes 8 key biomarkers: glucose, sodium, potassium, chloride, carbon dioxide (CO2), blood urea nitrogen (BUN), creatinine, and sometimes calcium. These markers assess blood sugar control, kidney function, and electrolyte balance.

No, A1C is not included in a basic metabolic panel. A1C requires a separate test and shows average blood sugar control over 2-3 months, while the basic metabolic panel only shows glucose levels at the moment of testing.

Yes, you should fast for 8-12 hours before a basic metabolic panel to ensure accurate glucose measurements. Water is usually allowed during fasting, but check with your healthcare provider about taking medications before the test.

Testing frequency depends on your health status. People with diabetes or kidney disease typically need quarterly testing, while healthy individuals often test annually during routine check-ups. Your healthcare provider may recommend more frequent testing based on your risk factors or health changes.

Diet, medications, hydration, and chronic conditions all shift basic metabolic panel results. Diuretics lower sodium and potassium; steroids raise glucose; dehydration concentrates BUN and creatinine. Acute illness and stress can also temporarily alter multiple markers simultaneously through hormonal and inflammatory responses.

References

  1. American Diabetes Association Professional Practice Committee (2024). 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes care, 47(Suppl 1), S20-S42. https://doi.org/10.2337/dc24-S002
  2. Selvin, E., Crainiceanu, C. M., Brancati, F. L., & Coresh, J. (2007). Short-term variability in measures of glycemia and implications for the classification of diabetes. Archives of internal medicine, 167(14), 1545-51. https://doi.org/10.1001/archinte.167.14.1545
  3. Peacock, M. (2010). Calcium metabolism in health and disease. Clinical journal of the American Society of Nephrology : CJASN, 5 Suppl 1, S23-30. https://doi.org/10.2215/CJN.05910809
  4. Thipsawat, S. (2021). Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature. Diabetes & vascular disease research, 18(6), 14791641211058856. https://doi.org/10.1177/14791641211058856
  5. Dhondup, T., & Qian, Q. (2017). Electrolyte and Acid-Base Disorders in Chronic Kidney Disease and End-Stage Kidney Failure. Blood purification, 43(1-3), 179-188. https://doi.org/10.1159/000452725
  6. Chatterjee, R., Davenport, C. A., Raffield, L. M., Maruthur, N., Lange, L., Selvin, E., Butler, K., Yeh, H. C., Wilson, J. G., Correa, A., Edelman, D., & Hauser, E. (2018). KCNJ11 variants and their effect on the association between serum potassium and diabetes risk in the Atherosclerosis Risk in Communities (ARIC) Study and Jackson Heart Study (JHS) cohorts. PloS one, 13(8), e0203213. https://doi.org/10.1371/journal.pone.0203213
  7. Tirosh, A., Shai, I., Tekes-Manova, D., Israeli, E., Pereg, D., Shochat, T., Kochba, I., Rudich, A., & Israeli Diabetes Research Group (2005). Normal fasting plasma glucose levels and type 2 diabetes in young men. The New England journal of medicine, 353(14), 1454-62. https://doi.org/10.1056/NEJMoa050080
  8. Dungan, K. M., Braithwaite, S. S., & Preiser, J. C. (2009). Stress hyperglycaemia. Lancet (London, England), 373(9677), 1798-807. https://doi.org/10.1016/S0140-6736(09)60553-5
  9. Tariq, M., Memon, M., Jafferani, A., Shoukat, S., Gowani, S. A., Nusrat, R., Riaz, M., Patel, J., Jamil, B., & Smego, R. A. (2009). Massive fluid requirements and an unusual BUN/creatinine ratio for pre-renal failure in patients with cholera. PloS one, 4(10), e7552. https://doi.org/10.1371/journal.pone.0007552
  10. Adrogué, H. J., & Madias, N. E. (2000). Hypernatremia. The New England journal of medicine, 342(20), 1493-9. https://doi.org/10.1056/NEJM200005183422006
  11. Hunter, R. W., & Bailey, M. A. (2019). Hyperkalemia: pathophysiology, risk factors and consequences. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 34(Suppl 3), iii2-iii11. https://doi.org/10.1093/ndt/gfz206
  12. Berend, K., van Hulsteijn, L. H., & Gans, R. O. (2012). Chloride: the queen of electrolytes?. European journal of internal medicine, 23(3), 203-11. https://doi.org/10.1016/j.ejim.2011.11.013
  13. Hussaini, M., Minhaj, R., Aishwarya, N., Kurapati, M., Al Khatib, Y., Yousuf, Z., Ibrahim Mohamed, M., Azam, R., A Orfali, H., & Abdul Mateen, M. (2024). Analysis of pH, electrolytes and non-invasive respiratory support in COPD with elevated CO. Bioinformation, 20(11), 1503-1507. https://doi.org/10.6026/9732063002001503
  14. Walker, M. D., & Shane, E. (2022). Hypercalcemia: A Review. JAMA, 328(16), 1624-1636. https://doi.org/10.1001/jama.2022.18331
  15. Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., Service, F. J., & Endocrine Society (2009). Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism, 94(3), 709-28. https://doi.org/10.1210/jc.2008-1410
  16. Spasovski, G., Vanholder, R., Allolio, B., Annane, D., Ball, S., Bichet, D., Decaux, G., Fenske, W., Hoorn, E. J., Ichai, C., Joannidis, M., Soupart, A., Zietse, R., Haller, M., van der Veer, S., Van Biesen, W., Nagler, E., & Hyponatraemia Guideline Development Group (2014). Clinical practice guideline on diagnosis and treatment of hyponatraemia. European journal of endocrinology, 170(3), G1-47. https://doi.org/10.1530/EJE-13-1020
  17. Matyukhin, I., Patschan, S., Ritter, O., & Patschan, D. (2020). Etiology and Management of Acute Metabolic Acidosis: An Update. Kidney & blood pressure research, 45(4), 523-531. https://doi.org/10.1159/000507813
  18. Cooper, M. S., & Gittoes, N. J. (2008). Diagnosis and management of hypocalcaemia. BMJ (Clinical research ed.), 336(7656), 1298-302. https://doi.org/10.1136/bmj.39582.589433.BE
  19. Meng, Q. H., & Wagar, E. A. (2015). Pseudohyperkalemia: A new twist on an old phenomenon. Critical reviews in clinical laboratory sciences, 52(2), 45-55. https://doi.org/10.3109/10408363.2014.966898
  20. Mozaffarian, D., Fahimi, S., Singh, G. M., Micha, R., Khatibzadeh, S., Engell, R. E., Lim, S., Danaei, G., Ezzati, M., Powles, J., & Global Burden of Diseases Nutrition and Chronic Diseases Expert Group (2014). Global sodium consumption and death from cardiovascular causes. The New England journal of medicine, 371(7), 624-34. https://doi.org/10.1056/NEJMoa1304127
  21. Sun, H., & Weaver, C. M. (2020). Rise in Potassium Deficiency in the US Population Linked to Agriculture Practices and Dietary Potassium Deficits. Journal of agricultural and food chemistry, 68(40), 11121-11127. https://doi.org/10.1021/acs.jafc.0c05139
  22. Ludwig, D. S. (2002). The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA, 287(18), 2414-23. https://doi.org/10.1001/jama.287.18.2414
  23. Pernicova, I., & Korbonits, M. (2014). Metformin--mode of action and clinical implications for diabetes and cancer. Nature reviews. Endocrinology, 10(3), 143-56. https://doi.org/10.1038/nrendo.2013.256
  24. Perez, A., Jansen-Chaparro, S., Saigi, I., Bernal-Lopez, M. R., Miñambres, I., & Gomez-Huelgas, R. (2014). Glucocorticoid-induced hyperglycemia. Journal of diabetes, 6(1), 9-20. https://doi.org/10.1111/1753-0407.12090
  25. Prasad, K. (2018). Does HbA1cc Play a Role in the Development of Cardiovascular Diseases?. Current pharmaceutical design, 24(24), 2876-2882. https://doi.org/10.2174/1381612824666180903121957
  26. Delgado, C., Baweja, M., Crews, D. C., Eneanya, N. D., Gadegbeku, C. A., Inker, L. A., Mendu, M. L., Miller, W. G., Moxey-Mims, M. M., Roberts, G. V., St Peter, W. L., Warfield, C., & Powe, N. R. (2022). A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. American journal of kidney diseases : the official journal of the National Kidney Foundation, 79(2), 268-288.e1. https://doi.org/10.1053/j.ajkd.2021.08.003
  27. Gröber, U., Schmidt, J., & Kisters, K. (2015). Magnesium in Prevention and Therapy. Nutrients, 7(9), 8199-226. https://doi.org/10.3390/nu7095388
  28. Biondi, B., Kahaly, G. J., & Robertson, R. P. (2019). Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders. Endocrine reviews, 40(3), 789-824. https://doi.org/10.1210/er.2018-00163
  29. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7), 412-9. https://doi.org/10.1007/BF00280883
  30. Broome, D. T., Pantalone, K. M., Kashyap, S. R., & Philipson, L. H. (2021). Approach to the Patient with MODY-Monogenic Diabetes. The Journal of clinical endocrinology and metabolism, 106(1), 237-250. https://doi.org/10.1210/clinem/dgaa710
  31. US Preventive Services Task Force, Davidson, K. W., Barry, M. J., Mangione, C. M., Cabana, M., Caughey, A. B., Davis, E. M., Donahue, K. E., Doubeni, C. A., Krist, A. H., Kubik, M., Li, L., Ogedegbe, G., Owens, D. K., Pbert, L., Silverstein, M., Stevermer, J., Tseng, C. W., & Wong, J. B. (2021). Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. JAMA, 326(8), 736-743. https://doi.org/10.1001/jama.2021.12531
  32. Kardalas, E., Paschou, S. A., Anagnostis, P., Muscogiuri, G., Siasos, G., & Vryonidou, A. (2018). Hypokalemia: a clinical update. Endocrine connections, 7(4), R135-R146. https://doi.org/10.1530/EC-18-0109
  33. Umpierre, D., Ribeiro, P. A., Kramer, C. K., Leitão, C. B., Zucatti, A. T., Azevedo, M. J., Gross, J. L., Ribeiro, J. P., & Schaan, B. D. (2011). Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA, 305(17), 1790-9. https://doi.org/10.1001/jama.2011.576
  34. Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., Nathan, D. M., & Diabetes Prevention Program Research Group (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England journal of medicine, 346(6), 393-403. https://doi.org/10.1056/NEJMoa012512

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey